Drug intelligence / Profile preview

Greffex Lyme vaccine

Development stage: Preclinical
Lead developer: Greffex
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
Administration: Intramuscular

Overview

The Greffex Lyme vaccine is a preclinical vaccine candidate developed using the company's proprietary Clean Ad adenoviral vector platform. This platform utilizes helper-dependent adenoviral vectors that are engineered to be devoid of all viral genes, which aims to minimize inflammatory responses and allow for the delivery of large genetic payloads. The vaccine is designed to prevent Lyme disease, caused by the bacterium *Borrelia burgdorferi*, by inducing an immune response against specific bacterial antigens. As of recent reports, the candidate is in the preclinical stages of development with plans to transition into clinical trials.

Other names: Greffex adenoviral Lyme vaccine

Beyond the preview

Go deeper on Greffex Lyme vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greffex Lyme vaccine.

Explore the full profile